long intergenic non-protein coding RNA 2153Genealiases: []
Q-omics provides the consensus-scored LINC02153 profile across patient tissues and cancer cell-line models. LINC02153 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02153 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, LINC02153 RNA expression shows 6,964 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LIHC, and STAD as cancer lineages where LINC02153 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02153 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02153 survival associations across molecular data types. LINC02153 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02153 RNA expression–survival associations across cancer types. High LINC02153 expression shows unfavorable associations in BRCA, ESCA, UCEC and KIRC, but favorable associations in LUAD and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02153 RNA expression.
This table summarizes LINC02153 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02153. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02153 shows lower tumor expression in LIHC, CHOL, KICH and COAD and higher tumor expression in KIRC. The LIHC box plot shows higher LINC02153 RNA expression in normal versus tumor tissue (log2 FC = −0.108, t-test p < 0.001).
This table shows molecular features associated with LINC02153 in patient tissues and cancer cell lines. In patient samples, LINC02153 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
